Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation

OBJECTIVES: Evaluating potential relationships between progression‐free survival (PFS) and tumor gene expression patterns and mutational status was an exploratory objective of the phase 3 TOURMALINE‐MM1 study (NCT01564537) of ixazomib‐lenalidomide‐dexamethasone (IRd) vs placebo‐Rd in 722 patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dash, Ajeeta B., Zhang, Jacob, Shen, Lei, Li, Bin, Berg, Deborah, Lin, Jianchang, Avet‐Loiseau, Hervé, Bahlis, Nizar J., Moreau, Philippe, Richardson, Paul G., Di Bacco, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497066/
https://www.ncbi.nlm.nih.gov/pubmed/32350909
http://dx.doi.org/10.1111/ejh.13435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497066/
https://www.ncbi.nlm.nih.gov/pubmed/32350909
http://dx.doi.org/10.1111/ejh.13435

Ejemplares similares